Reply: Value of tyrosinase RT–PCR in melanoma prognosis

por Gogas, H
Publicado 2003

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

por Gogas, H., Lofts, F. J., Evans, T. R., Daryanani, S., Mansi, J. L.
Publicado 1998

Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.

por Gogas, H., Lofts, F. J., Evans, T. R., Millard, F. J., Wilson, R., Mansi, J. L.
Publicado 1997

Biomarkers in melanoma

por Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.
Publicado 2009

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon

por Gogas, H, Kefala, G, Bafaloukos, D, Frangia, K, Polyzos, A, Pectasides, D, Tsoutsos, D, Panagiotou, P, Ioannovich, J, Loukopoulos, D
Publicado 2002

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases

por Armaou, S, Pertesi, M, Fostira, F, Thodi, G, Athanasopoulos, P S, Kamakari, S, Athanasiou, A, Gogas, H, Yannoukakos, D, Fountzilas, G, Konstantopoulou, I
Publicado 2009

Utility of adjuvant systemic therapy in melanoma

por Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., MacKie, R. M., Hauschild, A.
Publicado 2009

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

por Bafaloukos, D, Papadimitriou, C, Linardou, H, Aravantinos, G, Papakostas, P, Skarlos, D, Kosmidis, P, Fountzilas, G, Gogas, H, Kalofonos, C, Dimopoulos, A M
Publicado 2004

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

por Evans, T R J, Colston, K W, Lofts, F J, Cunningham, D, Anthoney, D A, Gogas, H, de Bono, J S, Hamberg, K J, Skov, T, Mansi, J L
Publicado 2002

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

por Koutras, A K, Kalogeras, K T, Dimopoulos, M-A, Wirtz, R M, Dafni, U, Briasoulis, E, Pectasides, D, Gogas, H, Christodoulou, C, Aravantinos, G, Zografos, G, Timotheadou, E, Papakostas, P, Linardou, H, Razis, E, Economopoulos, T, Kalofonos, H P, Fountzilas, G
Publicado 2008

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Publicado 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Publicado 2019